SCHEMBL21484744

SCHEMBL21484744

N#CCC(=O)Nc1nc(-c2ccc(C3CCCCC3)cc2)cs1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.60
MRE11 P49959 1/20 0.59
RAB9A P51151 4/20 0.59
NPC1 O15118 4/20 0.59
KDM4E B2RXH2 3/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
KMT2A Q03164 3/20 0.59
MAPT P10636 2/20 0.59
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 1/20 0.59
TRPA1 O75762 1/20 0.56
LMNA P02545 4/20 0.49
HTT P42858 2/20 0.49
ALOX12 P18054 1/20 0.49
MAPK1 P28482 1/20 0.49
POLB P06746 1/20 0.46
WNT3A P56704 1/20 0.46
ELOVL1 Q9BW60 2/20 0.45
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21516504 0.90 TRPA1 (0.57) ABL1MRE11RAB9ANPC1KDM4E
SCHEMBL4410774 0.85 TRPA1 (0.58) MRE11RAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL21484850 0.80 ABL1 (0.69) ABL1RAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL21484734 0.80 ABL1 (0.69) ABL1MRE11RAB9ANPC1KDM4E
SCHEMBL21484800 0.80 KMT2A (0.69) ABL1RAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL21484709 0.80 ABL1 (0.69) ABL1MRE11RAB9ANPC1KDM4E
SCHEMBL21484695 0.80 ABL1 (0.69) ABL1MRE11RAB9ANPC1KDM4E
SCHEMBL21484835 0.80 ABL1 (0.68) ABL1RAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL21484713 0.80 ABL1 (0.68) ABL1RAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL21484774 0.78 ABL1 (0.66) ABL1RAB9ANPC1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11453663-B2 Substituted propanamides as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2022-09-27 US disclosed
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-03-10 US disclosed
CN-112351983-A Substituted propionamides as inhibitors of nucleases 马萨里克大学 2021-02-09 CN disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073507-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES DNASE1, RNASEH1, FEN1 ABL1 4272/4885MRE11 86/4885RAB9A 2621/4885
US-11453663-B2 Substituted propanamides as inhibitors of nucleases DNASE1, RNASEH1, FEN1 ABL1 4272/4885MRE11 86/4885RAB9A 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.